Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Outcomes Of Relapse Of AML Post Allogeneic Transplantation In The Era Of Hypomethylating Agents: An Analysis Of 162 Allogeneic Transplants From a Single Center

Justin LaPorte, PharmD, BCOP, Xu Zhang, PhD, Zaamin Hussain, Stacey Brown, BA, Connie A. Sizemore, PharmD, Melissa Sanacore, PharmD, Ronald Mihelic, PharmD, BCOP, Mindy Leech, PharmD, Lawrence E. Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD, Asad Bashey, MD, PhD

Blood (2013) 122 (21): 2086.

https://doi.org/10.1182/blood.V122.21.2086.2086

Published: 2013

Journal Articles

Calcineurin Inhibitor-Free GVHD Prophylaxis with Post-Transplant Cyclophosphamide and Brief-Course Sirolimus Results in Low Rates of Non-Relapse Mortality and Chronic GVHD Following Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation (PBSCT)

Melissa Sanacore, PharmD, Asad Bashey, MD, PhD, Connie A. Sizemore, PharmD, H. Kent Holland, MD, Lawrence E. Morris, MD, Stacey Brown, B.A., Xu Zhang, PhD, Scott R. Solomon, MD

Blood (2013) 122 (21): 923.

https://doi.org/10.1182/blood.V122.21.923.923

Published: 2013

Journal Articles

Maintenance Hypomethylating Therapy Post Allogeneic Stem Cell Transplantation Provides Favorable Progression Free Survival in High Risk Acute Myelogenous Leukemia or Non Responsive Myelodysplastic Syndrome

Connie A. Sizemore, PharmD, Xu Zhang, PhD, Melissa Sanacore, PharmD, Asad Bashey, MD, PhD, Scott R. Solomon, MD, Lawrence E. Morris, Jr., MD, H. Kent Holland, MD

Blood (2012) 120 (21): 4468.

https://doi.org/10.1182/blood.V120.21.4468.4468

Published: 2012

Journal Articles

Lineage–Specific Chimerism and Incidence of Graft-Failure Following T-Cell Replete Haploidentical Transplantation Using Post-Transplant Cyclophosphamide in Eighty-Nine Consecutive Patients From a Single-Center.

Amaani Hussain, Connie A. Sizemore, PharmD, Xu Zhang, PhD, Melissa Sanacore, PharmD, Stacey Brown, B.A., Karen Manion, RN, Lawrence E. Morris, Jr., MD, H. Kent Holland, MD, Scott R. Solomon, MD, Asad Bashey, MD, PhD

Blood (2012) 120 (21): 3030.

https://doi.org/10.1182/blood.V120.21.3030.3030

Published: 2012

Journal Articles

T-Cell Replete Haploidentical Transplantation Using Post-Transplant Cyclophosphamide Results in Equivalent Non-Relapse Mortality and Disease-Free Survival Compared to Transplantation From HLA-Identical Sibling and Matched Unrelated Donors: A Stratified Cox Model Analysis of Two Hundred and Sixty Contemporaneous Allogeneic Transplants From a Single Center

Asad Bashey, MD, PhD, Xu Zhang, PhD, Connie A. Sizemore, PharmD, Karen Manion, RN, Stacey Brown, BA, H. Kent Holland, MD, Scott R. Solomon, MD, Lawrence E. Morris, MD

Blood (2011) 118 (21): 833.

https://doi.org/10.1182/blood.V118.21.833.833

Published: 2011

Journal Articles

Haploidentical Transplantation Using T-Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors Is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of A Prospective Phase II Trial

Connie A. Sizemore, PharmD, Asad Bashey, MD, PhD, Melissa Sanacore, PharmD, Karen Manion, RN, H. Kent Holland, MD, Lawrence E. Morris, MD, Stacey Brown, B.A., Xu Zhang, PhD, Scott R. Solomon, MD

Blood (2011) 118 (21): 889.

https://doi.org/10.1182/blood.V118.21.889.889

Published: 2011

Journal Articles

Low Dose Subcutaneous Alemtuzumab and Preemptive Donor Lymphocyte Infusion without Withdrawal of Immunosuppression Results in Low Non-Relapse Mortality, Decreased Hospitalization, and Favorable Outcomes for High Risk Older Recipients of Unrelated Donor Allogeneic Transplants: A Prospective Phase II Trial

Connie A. Sizemore, PharmD, Asad Bashey, MD, PhD, Karen Manion, RN, H. Kent Holland, MD, Lawrence E. Morris, MD, Stacey Brown, BA, Xu Zhang, PhD, Scott R. Solomon, MD

Blood (2011) 118 (21): 3016.

https://doi.org/10.1182/blood.V118.21.3016.3016

Published: 2011

Journal Articles

An Effective Hematopoietic Stem Cell Mobilization Algorithm for Adding Plerixafor to G-CSF for Multiple Myeloma Patients Undergoing Autologous Transplantation

Justin LaPorte, PharmD, BCOP, Scott R. Solomon, MD, Asad Bashey, MD, PhD, H. Kent Holland, MD, Lawrence E. Morris, Connie A. Sizemore, PharmD, Melissa Sanacore, PharmD, Ronald Mihelic, PharmD, BCOP, Mindy Leech, PharmD, Irina Grigorieva, PhD, Xu Zhang, PhD

Blood (2011) 118 (21): 4389.

https://doi.org/10.1182/blood.V118.21.4389.4389

Published: 2011

NARROW

Outcomes Of Relapse Of AML Post Allogeneic Transplantation In The Era Of Hypomethylating Agents: An Analysis Of 162 Allogeneic Transplants From a Single Center

Calcineurin Inhibitor-Free GVHD Prophylaxis with Post-Transplant Cyclophosphamide and Brief-Course Sirolimus Results in Low Rates of Non-Relapse Mortality and Chronic GVHD Following Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation (PBSCT)

Maintenance Hypomethylating Therapy Post Allogeneic Stem Cell Transplantation Provides Favorable Progression Free Survival in High Risk Acute Myelogenous Leukemia or Non Responsive Myelodysplastic Syndrome

Lineage–Specific Chimerism and Incidence of Graft-Failure Following T-Cell Replete Haploidentical Transplantation Using Post-Transplant Cyclophosphamide in Eighty-Nine Consecutive Patients From a Single-Center.

Haploidentical Transplantation Using T-Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors Is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of A Prospective Phase II Trial

An Effective Hematopoietic Stem Cell Mobilization Algorithm for Adding Plerixafor to G-CSF for Multiple Myeloma Patients Undergoing Autologous Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only